Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | UBE2M | P61081 | 1/20 | 0.34 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6038158 | 0.86 | DDR2 (0.39) | DDR2MAPK14EPHX1TP53LMNA | |
| SCHEMBL6038138 | 0.81 | MAPT (0.50) | DDR2MAPK14TP53LMNA | |
| SCHEMBL6037978 | 0.79 | LMNA (0.47) | DDR2MAPK14TP53LMNA | |
| SCHEMBL5282375 | 0.79 | AOC3 (0.47) | DDR2MAPK14TP53LMNA | |
| SCHEMBL6037944 | 0.79 | LMNA (0.48) | DDR2MAPK14TP53LMNA | |
| SCHEMBL5279990 | 0.78 | ROCK2 (0.46) | DDR2MAPK14LMNA | |
| SCHEMBL6038109 | 0.77 | DDR2 (0.51) | DDR2MAPK14TP53LMNA | |
| SCHEMBL6038350 | 0.77 | DDR2 (0.42) | DDR2MAPK14LMNA | |
| SCHEMBL6038018 | 0.76 | RAB9A (0.48) | — | |
| SCHEMBL5280368 | 0.75 | RAB9A (0.43) | DDR2TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | claimed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | DDR2 3735/4885MAPK14 3936/4885EPHX2 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.